The FDA has approved Capsida Biotherapeutics' investigational new drug (IND) application for CAP-003 to treat Parkinson’s ...

Ocugen, Inc. (NASDAQ: OCGN) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 2/3 ...

Supply chains for a new generation of therapies are complex, costly, and require meticulous management to ensure patient ...

The US Food and Drug Administration (FDA) has approved Ocugen’s investigational new drug (IND) amendment to initiate a Phase ...

For gene therapy developers ... optimising research processes for large-scale and GMP applications presents additional difficulties. AI algorithms can help identify capsid variants that are ...

Participants with Duchenne muscular dystrophy (DMD) who received RGX-202 demonstrated functional improvement and better ...

Showcased 7 presentations at ISSCR 2025, including a featured oral presentation on first-in-human gene therapy for heart ...

The OCU410ST Phase 2/3 pivotal confirmatory trial represents a major advancement as Ocugen's second late-stage clinical program. Ocugen plans to submit a BLA for OCU410ST in 2027 in alignment with its ...

In this interview, we explore the limitations of pDNA, the advantages of mcDNA and how NunaBio’s technology could unlock new ...

ROCKVILLE, MD / ACCESS Newswire / June 16, 2025 /uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to ...

How can early decisions in cell and gene therapy clinical development impact downstream progress toward commercialization and ...

While commercial uptake by patients still lags and a recent court decision rekindles a legal battle, clinical successes ...